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Abstract
Background: Effective and safe anticoagulative therapy needs close co-operation between
doctor and patient, the latter being well-informed. The aim of the study was to assess knowl-
edge of oral anticoagulation in a group of patients with atrial fibrillation (AF) treated with
acenocoumarol and to determine the relationship between knowledge and INR value.
Method: The study group consisted of patients with AF who were continuously using antico-
agulative therapy and who were admitted to hospital (for different reasons). The questionnaire
comprised questions about their knowledge of various aspects of the treatment used. In the
assessment of knowledge a numerical scale was introduced (0–9 points) and the patients were
given one point for each correct answer.
Results: The study group consisted of 61 patients aged 46–91 (mean 70.18). The level of
knowledge of oral anticoagulation among the group of patients examined was low (the mean
number of points achieved was 4.19 in the 9-point scale). Sex, education and the reason for
admission had no relationship with the level of knowledge. Younger patients (4.85 ± 1.94 vs.
3.56 ± 1.86, p = 0.01) and those who had INR within the therapeutic limits at the moment of
admission to the hospital (5.50 ± 1.79 vs. 3.56 ± 1.79 points, p = 0.0003) had a higher level
of knowledge of the antithrombotic treatment.
Conclusions: Knowledge of treatment with acenocoumarol among the patients with atrial
fibrillation using oral anticoagulation is low and inversely correlated with age. The greater the
knowledge, the better is the value of INR controlled. (Cardiol J 2007; 14: 44–49)
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Introduction
Antithrombotic prophylaxis is absolutely
essential for a modern and rational therapy for
patients with atrial fibrillation at particular risk of
cerebral stroke. The introduction and proper mon-
itoring of prolonged anticoagulation is probably
more important for patients than taking a decision
about the conversion of atrial fibrillation to a nor-
mal sinus rhythm [1]. Prolonged oral anticoagula-
tion with proper control of the INR decreases the
risk of a cerebral stroke by 2/3 times [2], which
means a longer life and the prevention of perma-
nent disability among patients with atrial fibrillation.
Despite the very encouraging results of clini-
cal studies and their transposition to the official
guidelines of cardiological societies [3–5], the fre-
quency with which anticoagulative drugs are admin-
istered to those patients with atrial fibrillation with
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additional risk factors of cerebral stroke is still
alarmingly low [6, 7]. The essential factors respon-
sible for this are physicians’ fears of the complica-
tions associated with oral anticoagulation and the
restrictive nature of the treatment, which is tiring
for the patient. In addition, it appears that even
among patients using antimetabolites of vitamin K
on medical advice the number of checks on the INR
value within the therapeutic limits varies by about
40% [8].
The specificity of prolonged oral antithrombotic
prophylaxis requires continual co-operation be-
tween the doctor and a well-informed patient. It
would appear that knowledge and a good under-
standing of oral anticoagulation by the patient is
essential for the increased effectiveness and safe-
ty of the anticoagulative procedure. Explaining the
aims of the therapy to the patient is a condition of
their proper motivation towards their treatment;
the effectiveness of the treatment requires know-
ledge of its rules and its safety depends on the pa-
tient’s awareness of possible side effects and of
their symptoms. In spite of this many studies indi-
cate that there are serious gaps in the education of
patients with atrial fibrillation taking oral anticoag-
ulants [9–14].
The aim of the study was to assess the level of
knowledge of oral anticoagulation and the correla-
tion between this and INR in a group of patients with
atrial fibrillation being treated with acenocoumarol.
Methods
The prospective study group consisted of
61 patients with a history of AF (paroxysmal, per-
sistent or permanent) on prolonged oral antithrom-
botic prophylaxis who were admitted to hospital
from the emergency department in 2005.
All the patients were asked to give their basic
demographic data. Using anamnesis and medical
history if available the character of the AF in the
past was determined (paroxysmal, persistent or
permanent) as well as concomitant illnesses which
could influence the use of oral anticoagulation and
the limits of therapeutic INR.
To evaluate their knowledge of antithrombot-
ic prophylaxis all the patients examined were asked
questions by a doctor and had a questionnaire to
complete. The questions dealt with awareness of
the antithrombotic therapy, knowledge of the name
of the drug used and the aim of the treatment,
knowledge of the influence of alcohol, diet and oth-
er drugs on the efficiency and safety of the therapy
used and knowledge of the side effects of treatment
with acenocoumarol and the symptoms of these. To
assess the level of knowledge a point-scale was
used, one point being given for each correct answer.
In addition, one question was included which re-
quired subjective evaluation of the degree of wea-
riness experienced with the treatment used.
To assess the propriety of the control of the
antithrombotic prophylaxis all the patients had their
INR checked on admission. Values between 2.0 and
3.0 [3–5] were taken as the proper ones, apart from
those of patients with an artificial valve, for whom
the optimum limits depended on the recommenda-
tions for the particular valve [15].
The data received was statistically analysed by
the use of the STATISTICA program. The contin-
uous variables were given as the mean ± standard
deviation. The significance of the differences ob-
served between the results obtained was described
by the use of Student’s t-test and the c2 test of in-
dependence. Models of multifactorial regression
analysis were also used. P < 0.05 was taken as the
significance level.
Results
The study group consisted of 61 patients,
32 women and 29 men, aged 46–91 (mean age 70.2 ±
± 10.5), of whom 18 (30%) had a therapeutic value
of INR on admission, 19 (31%) had a value which
was too low and 24 (39%) a value which was too
high. The characteristics of the group divided into
two subgroups for those with and those without an
INR therapeutic value, are shown in Table 1.
Of the group studied 57 people (93%) realised
that they were being treated with a drug which re-
duced the ability of blood to coagulate (“blood thin-
ning”). However, only 42 of them (69%) could give
(more or less precisely) the name of a drug with
such characteristics (Acenocumarol®, Sintrom®,
Syncumar®).
The questions answered by the patients were
of the multiple-choice type. In the question about
the aim of the antithrombotic therapy, 19 answers
(30%) were accepted as correct and 16 people gave
the correct answer “cerebral stroke prophylaxis”.
Two of them associated antithrombotic prophylax-
is with former implantation of an artificial valve and
one associated treatment with acenocoumarol with
emboli in the arteries of the lower extremities.
A total of 18 patients thought that the aim of aceno-
coumarol was the prevention of a repeat of paroxysms
of AF, 14 of them stated that the main aim of treat-
ment was prevention of myocardial infarction and
24 members of the group could not provide any answer.
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The great majority, 51 patients (84%), were
aware that the consumption of alcohol was not indi-
cated during treatment with oral anticoagulants. When
asked about drugs which increased the power of
acenocoumarol 19 patients (31%) named acetylsali-
cylic acid (Aspirin®). Only a small number, 4 patients
(7%), were aware of the influence on treatment of
the consumption of a large amount of green vegeta-
bles. Only 8 patients (13%) knew that they would
need to avoid, if possible, intra-muscular injections.
Although only 16 patients (26%) indicated
haemorrhaging from the gastrointestinal system as
a possible complication of the treatment used, 36 of
them (59%) knew that the appearance of black fae-
ces was a warning symptom requiring immediate
contact with a doctor. The percentage of correct an-
swers to questions dealing with different aspects of
antithrombotic prophylaxis is shown in Figure 1.
The subjects examined were awarded scores
between 0 and 8 points (mean 4.19) on a 9-point
scale. The number of points achieved was depend-
ent on neither sex nor education but on the age of
those examined (mean age: 70 years, younger vs.
older: 4.85 vs. 3.56 points, p = 0.01). With respect
to knowledge among patients with permanent and
paroxysmal/persistent AF, there was no demonstra-
ble difference. The fact of cerebral stroke in their
medical history did not change the level of knowledge.
Similarly, there was no statistically important differ-
ence between patients when grouped according to the
cause of admission (heart failure, pneumonia or haem-
orrhagic complication). There was a statistically sig-
nificant difference between the number of points
achieved by patients with a therapeutic INR and those
with INR outside that value. The patients with an INR
within the advisory limits were awarded 5.5 points on
average, while those with an INR lower or higher than
the therapeutic limits were awarded 3.56 points
(p = 0.0003, Table 2). The above results were con-
firmed in a multifactorial analysis of regression, which
showed a significant correlation between age and the
therapeutic value of INR and the number of points
achieved in the test (Table 3).
One question concerned the inconvenience asspcia-
ted with chronic anticoagulation. In response to this
21 subjects pointed out the necessity of systematic blood
checks as the main problem, 9 the fear of complications
caused by the treatment, 4 the cost of the medication
and 1 the necessity of taking the medicine every day.
At the same time 32 patients (52%) saw no inconve-
nience connected with the treatment administered.
Discussion
To sum up, we observed that among patients
with AF who used chronic antithrombotic prophylaxis
Table 1. Characteristics of group studied with division into therapeutic and non-therapeutic INR.
Generally Therapeutic INR Non-therapeutic INR p
N 61 18 43
Male 29 9 (50%) 20 (46.5%) NS
Mean age ± SD 70.2 68.11 71.05 NS
Patients with secondary or higher education 31 12 (66.7%) 19 (44.2%) NS
Patients with permanent atrial fibrillation 51 14 (77.8%) 37 (86.1%) NS
Patients after stroke 17 7 (38.9%) 10 (23.3%) NS
Patients with heart failure 24 10 (55.6%) 14 (32.6%) NS
Patients with pneumonia 12 3 (16.7%) 9 (20.9%) NS
Patients with haemorrhagic complication 9 1 (5.6%) 8 (18.6%) NS
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Consciousness of antithrombotic therapy
Knowledge of the influence of alcohol
Knowledge of name of drug
Knowledge of warning symptoms
Knowledge of the aim of therapy
Knowledge of  the influence
of acetylsalicylic acid
Awareness of possible bleeding complications
Knowledge of the  necessity of
avoiding intramuscular injections
Knowledge of the influence of diet
Figure 1. Knowledge of the particular aspects of antith-
rombotic treatment in the group studied. Figures indi-
cate the percentage of correct answers.
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and were admitted to hospital the level of know-
ledge about their therapy was low (4.19 points on
the 9-point scale) and inversely correlated with age.
Patients with an INR value on admission within the
therapeutic limits had a higher score in our ques-
tionnaire.
Guidelines currently being published for the
management of patients with AF underline the role
of the education of the patient in the treatment of
chronic diseases of the circulatory system [16–18].
Simultaneously, there are reports which emphasise
the level of knowledge of the individuals treated,
which remains low [19, 20]. Prolonged oral anti-
thrombotic prophylaxis can serve as a model of
medical management which needs the conscious co-
operation of the patient when taking decisions about
the beginning of therapy, its prolongation, its con-
trol and also the prevention and early discovery of
side effects. This necessary co-operation is possi-
ble only in the case of patients who have some
awareness of the aims, rules, advantages and dan-
gers of the treatment being used.
Bearing this in mind, many authors in differ-
ent countries have studied the level of education
among patients using antimetabolites of vitamin K
[9–14]. Although these researchers have construct-
ed their questionnaires in different ways, most have
included questions dealing with the patient’s under-
standing of the aim of the therapy, its possible side
effects and interactions with other drugs. The gen-
eral conclusion of all these studies has been that the
level of knowledge of those questioned is alarmingly
low. Some authors have attempted a quantitative
evaluation of the mean level of education of the in-
dividuals examined [11, 12, 14]. Although different
questionnaires and different ways of evaluating the
results have been used, their results were very similar
to those presented in this study (0.48 of the 1.00 pos-
sible in the study of Tang et al. [11], 7.14 on a 15-point
scale in de Felipe Medina’s study [12] and 6.63 out
of 12 possible points in Salgari’s et al. study [14]).
It is generally considered that introducing an-
tithrombotic therapy among older people is espe-
cially difficult, not only in view of the increased
risk of bleeding but also of the more problematic
co-operation both in the treatment and in its moni-
toring [21]. Tang et al. [11] underline in their study
that the level of knowledge about oral anticoagula-
tion among older people is lower. Similarly, we have
demonstrated in our study a statistically significant
difference in the level of knowledge between young-
er and older people. We did not, however, demon-
strate a correlation between age per se and a prop-
er control of INR.
There is one especially interesting question:
to what extent is the knowledge of those treated
correlated with proper control of INR and with the
effectiveness and safety of the therapy that this
implies? In de Felipe Medina’s study [12], which
was specifically designed to answer this question,
no significant correlation was demonstrated be-
tween the level of knowledge of people filling in the
questionnaire and the number of checks of INR
within the therapeutic limits. On the other hand,
Table 2. The score obtained in the test.
Male vs. female 4.07 ± 1.94 vs. 4.19 ± 2.05 NS
Age: £ 70 years vs. > 70 years 4.85 ± 1.94 vs. 3.56 ± 1.86 0.01
Education: primary and technical vs. secondary and higher 3.87 ± 1.93 vs. 4.39 ± 2.04 NS
Atrial fibrillation: permanent vs. paroxysmal/persistent 4.06 ± 1.91 vs. 4.50 ± 2.42 NS
After stroke vs. without stroke 4.59 ± 1.94 vs. 3.95 ± 2.00 NS
Heart failure vs. without heart failure 4.00 ± 1.68 vs. 4.22 ± 2.19 NS
Pneumonia vs. without pneumonia 4.08 ± 1.98 vs. 4.14 ± 2.01 NS
Haemorrhagic complication vs. without haemorrhagic complication 3.44 ± 2.36 vs. 4.25 ± 1.92 NS
INR therapeutic vs. INR non-therapeutic 5.50 ± 1.79 vs. 3.56 ± 1.79 0.0003
Table 3. Multifactorial analysis of regression




Type of atrial fibrillation 0.006347 NS
Stroke in anamnesis 0.066706 NS
Education 0.072489 NS
Therapeutic INR 0.0372786 0.001887
Heart failure –0.114550 NS
Haemorrhagic complication –0.058706 NS
Pneumonia 0.068917 NS
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in the study by Tang et al. [11] study a positive cor-
relation was indeed shown between level of knowl-
edge and the correctness of control of INR during
visits before the study. The most interesting results
are those of Saligari et al. [14]. These demonstrated
that the greater the knowledge of patients (associa-
ted with the introduction of an educational pro-
gramme), the more the INR checks fell within the
therapeutic limits. All the above studies were based
on the populations of antithrombotic clinics and
medical documents, including a series of INR re-
sults, could be checked. In our study of necessity
we based our research on a single check on the day
of admission to hospital. Although we showed
a correlation between the level of knowledge and
the INR value, we were conscious that the value of
a single check is obviously very limited as far as an
evaluation of the quality of control of anticoagula-
tion goes. On the other hand, it is worth observing
that even episodic INR beyond the therapeutic value
can be a reason for the ineffectiveness of treatment,
its complications or the necessity for hospitalisation.
The problem of correlation between level of
knowledge and quality of control of oral anticoagu-
lation was studied by Arnsten et al. [22] in a slight-
ly different way. They compared a group of patients
being monitored in a health centre supervising an-
ticoagulative therapy and a group of patients who
had unilaterally stopped taking the medicine or had
been excluded from the centre because of lack of
co-operation. The researchers showed that patients
who broke the contact with the centre were young-
er, had less understanding of the aims of the thera-
py and complained about worse contact with their
doctor. The last finding provides us with a chance
to discover why there is such a low level of knowl-
edge in patients and to have the opportunity to im-
prove it.
The education of a patient using oral anticoag-
ulants is difficult and time-consuming. It should
begin from the very moment the decision is taken
together by the doctor and patient to introduce the
drug and should continue throughout the whole
period of treatment. The conscious and active par-
ticipation of the patient in the process of treatment
needs information from the doctor about their sub-
jective role plus explanations of the aim of the ther-
apy used, its expected benefits and possible disad-
vantages. Alternative methods should also be pre-
sented and, finally, the doctor must record that
a patient has understood all the above information.
Braddock et al. [23] analysed over 1000 records of
visits with regard to the components in the relation-
ship between doctor and patient. In the case of
a decision being taken to introduce a new drug, none
of the dialogues contained all the components stated.
The advantages of educational programmes were pre-
sented in a study already cited by Saligari et al. [14].
Considering the time constraints between doctor
and patient, as well as the complexity of antithrom-
botic therapy in patient education, the use of spe-
cial instructional materials is advised [24].
It is thought that well-educated patients are
characterised by their greater acceptance of anti-
thrombotic therapy [24, 25]. Paradoxically, in our
study, despite their poor level of knowledge, more
than half of those questioned did not inform the
researchers of any problems with their treatment.
What is significant is that only nine people verbal-
ised a fear of possible complications of the therapy.
The limitation of the study was the fact that it
was based on patients admitted to hospital and not
patients at an antithrombotic clinic. Taking into
consideration that some of them were admitted to
hospital because of incorrect control of anticoagu-
lation, one may predict that the knowledge in the
group studied was inferior to that among people
treated in this way when taken as a whole. Never-
theless, it is the over-represented group in our
study which needs special care and education. The
group studied was relatively small, which consti-
tutes the other limitation, but this is mainly a re-
sult of the continuing low frequency of administra-
tion of anticoagulative drugs in the group of patients
with AF. Nevertheless, considering the importance
of the matter and, as we saw it, the interest of our
findings, we decided to terminate the study after
one year and to present the results.
Conclusions
1. The level of knowledge about treatment with
acenocoumarol among patients with atrial fibril-
lation who are admitted to hospital and are us-
ing oral anticoagulative therapy is low. Patients
over 70 years of age have a lower level of
knowledge than younger ones.
2. The low level of knowledge about oral antico-
agulation is a risk factor in the improper con-
trol of the INR value.
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